AMRI’s growth strategy, which has included a mix of organic and inorganic growth through acquisitions between 2014 and 2016, is bringing new technologies and capabilities to the Pharma/Biopharma industry. AMRI has significantly expanded its portfolio of niche, high-barrier-to-entry APIs; expanded its global footprint, especially as it relates to capabilities and capacity in Europe; and has continued to bring customers new/expanded capabilities and technologies to help accelerate their projects across the drug discovery and development continuum.
AMRI celebrates its 25-year anniversary in 2016 as a premier provider of global discovery, development and manufacturing services:
25 years delivering market-transforming Medicinal Chemistry
Significantly expanded Biology Services led by pharma-industry experts
Leader in the research, development and manufacture of complex APIs
World-class Drug Product Manufacturing, including aseptic formulation and sterile fill-and-finish
Over 3,000 employees globally
Building a premier supplier of contract research, development and manufacturing services organization requires an understanding of the marketplace, a long-term strategy for inorganic and organic growth and the ability to effectively integrate acquisitions. Contact us to find out more about AMRI’s services and products.